NCT04264546View on ClinicalTrials.gov

Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib)

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

November 24, 2017

Primary Completion Date

March 9, 2018

Study Completion Date

December 28, 2018

Conditions
Polio
Interventions
BIOLOGICAL

sIPV

The investigational High dosage Sabin IPV was all developed by Minhai Biotech Co., LTD. The antigen contents of type I, type II and type III polioviruses in the high dosage Sabin IPV were 22 DU, 65 DU and 65 DU. The vaccine was in liquid form, 0.5 ml per dose.

Trial Locations (1)

Unknown

Jiangsu Provincial Center for Disease Control and Prevention, Nanjing

All Listed Sponsors
lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT04264546 - Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib) | Biotech Hunter | Biotech Hunter